Hrubá marža spoločnosti Cotinga Pharmaceuticals
Aká je hodnota metriky Hrubá marža spoločnosti Cotinga Pharmaceuticals?
Hodnota metriky Hrubá marža spoločnosti Cotinga Pharmaceuticals, Inc. je N/A
Aká je definícia metriky Hrubá marža?
Hrubá marža (Gross margin) je rozdiel medzi príjmami a nákladmi na predaný tovar vydelený príjmami a vyjadrený v percentách.
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
Čomu sa venuje spoločnosť Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.